Symax-SL

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Symax-SL

Property Description
Active ingredient Hyoscyamine Sulfate
Form Orally Disintegrating Tablet (Sublingual)
Pharmacological class Anticholinergic / Antispasmodic
General purpose Relieving spasms and cramps in smooth muscles
Origin Semi-synthetic Tropane Alkaloid

Symax-SL is a prescription-only pharmaceutical preparation whose single active component, Hyoscyamine Sulfate, classifies it primarily as an Anticholinergic and Antispasmodic medication. Its primary role is to selectively inhibit involuntary nervous system signals that cause hyperactivity in smooth muscle tissues. Hyoscyamine is a semi-synthetic derivative of a natural Tropane Alkaloid found in plants of the Solanaceae family.


What Type of Medicine is Symax-SL?

Symax-SL is classified as an Anticholinergic (or Parasympatholytic) drug because it works by blocking the action of the neurotransmitter Acetylcholine at certain nerve receptors. This pharmacological class is defined by its ability to decrease the responsiveness of involuntary systems responsible for functions like muscle contractions and gland secretions. The benefit of this specific mechanism is the ability to calm muscle overactivity throughout the body by targeting the underlying nerve signals, helping manage conditions characterized by spasticity, such as general abdominal cramping.


Composition and Sublingual Form

The medicine is a single-ingredient product containing only Hyoscyamine Sulfate and is formulated as an Orally Disintegrating Tablet (Sublingual Tablet). This specialized dosage form is designed to dissolve rapidly when placed under the tongue, facilitating its absorption through the sublingual tissues. This unique design for sublingual administration is intended to provide a quick onset of action, which is a distinctive advantage of this formulation when compared to traditional, swallowed tablets.


Symax-SL's General Purpose

The general purpose of Symax-SL is to help relieve painful cramping and discomfort that result from the hyperactive contractions of smooth muscles, particularly in the gastrointestinal and urinary tracts. By acting as a powerful Antispasmodic, it decreases the propulsive motility and excessive secretions in these organs. This inhibitory action helps the affected smooth muscles relax, thereby easing general discomfort. Anticholinergics like Hyoscyamine are utilized for their ability to manage conditions involving uncontrolled muscle spasms.

Regulatory References

  1. Hyoscyamine Sulfate (DailyMed/NIH)
  2. FDA-Approved Labeling (via DailyMed)
  3. FDA Label on Antispasmodic Use

What side effects are possible with Symax-SL?

Possible Side Effects and Safety Information

The safety profile of Symax-SL (Hyoscyamine Sulfate) is consistent with its classification as an anticholinergic agent, with most documented adverse reactions resulting from the inhibition of involuntary nerve signals.

Adverse Reactions by Physiological System

Adverse effects are officially documented across several System-Organ Classes, though the specific frequency for most listed effects is typically not reported in regulatory summaries. Effects generally stem from the drug's core action, impacting systems responsible for fluid balance and muscle movement.

System-Organ Class Examples of Documented Effects
Gastrointestinal Dryness of the mouth, constipation, nausea, vomiting, bloated feeling.
Nervous System Headache, drowsiness, dizziness, weakness, nervousness.
Ocular Blurred vision, mydriasis, increased ocular tension.
Cardiac Tachycardia (fast heart rate), palpitations.
Urinary Urinary hesitancy, urinary retention.

Serious Adverse Reactions and Safety Considerations

The labeling identifies certain serious adverse reactions and specific risks. Psychosis, involving symptoms such as mental confusion and hallucinations, has been reported in sensitive individuals, with CNS effects documented to resolve within 12 to 48 hours after discontinuation. The drug's capacity to reduce sweating creates an environmental risk of Heat Prostration (fever/heat stroke), particularly in high temperatures.

Older adults are officially noted as being especially susceptible to common anticholinergic effects like mental confusion, urinary retention, and constipation. Patients with renal impairment may face a greater risk of toxic reactions as the drug is substantially excreted by the kidney. Furthermore, the medication may produce effects that restrict activities requiring mental alertness, such as drowsiness or blurred vision.

Overdose and Emergency Response

Overdose of Hyoscyamine Sulfate (Symax-SL) is characterized by documented signs of anticholinergic toxicity. Regulator-listed clinical manifestations include dilated pupils, blurred vision, tachycardia, dryness of the mouth, and hot, dry skin, often accompanied by headache and urinary difficulty. Severe outcomes documented in official labeling involve CNS stimulation, confusion, hallucinations, psychosis, and potentially life-threatening manifestations such as coma or paralysis of the respiratory muscles.

Emergency Action Mandate

Due to the risk of severe outcomes, individuals must seek immediate medical attention upon any suspicion of overdose. Regulatory guidance specifies initial interventions, including immediate lavage of the stomach. The specific antidote documented for treating the acute anticholinergic effects is physostigmine injection, which is administered intravenously under medical supervision. Supportive measures for managing severe toxicity may include artificial respiration if respiratory muscle paralysis occurs, and techniques like tepid water sponge baths for symptomatic fever control. Regulatory information notes that patients with impaired renal function may have an increased risk of toxic reactions, while children taking high doses are susceptible to a paradoxical hyperexcitability reaction.

Therapeutic Uses of Symax-SL

What Symax-SL Treats: Main Uses and Benefits

The primary role of Symax-SL is to provide supportive symptomatic relief across key therapeutic domains where symptoms related to heightened physiological activity and excessive fluid production are present. It is commonly used in areas where short-term symptom management is appropriate.

This medication is generally applied in addressing conditions characterized by periods of heightened symptoms such as Irritable Bowel Syndrome (IBS), Diverticulitis, and acute episodes like Renal or Biliary Colic. It is also relevant for easing certain distressing symptoms of spasm within the urinary tract (e.g., bladder spasms) and is used as an adjunct for conditions like Peptic Ulcer Disease to address symptoms of hypersecretion.

“The supportive action supports patients during episodes of heightened discomfort by addressing symptoms that create noticeable physiological strain.”

The core therapeutic goal is to may assist with easing the intensity of sharp, episodic pain and may assist with addressing discomfort and urgency associated with bowel or urinary tract spasms. It also is applied in addressing conditions marked by sialorrhea (excessive salivation). This provides support that helps ease the overall symptom burden.


Quick Fact: Supportive Management of Visceral Spasms

The medication is relevant when short-term symptomatic assistance is needed to address acute, painful manifestations in the gastrointestinal and urinary systems.

Regulatory References

  1. Official Medication Label (DailyMed)

Eligibility and Restrictions for Use

Eligibility Map: Official Regulatory Information

This section outlines the official population eligibility and non-eligibility rules for Symax-SL (Hyoscyamine Sulfate), based strictly on government regulatory documents.


Eligibility scope

Populations for whom use is allowed (as stated in label):

  • Adults and adolescents 12 years of age and older.
  • Pediatric patients 2 to under 12 years of age (use established, but with specific warnings).

Populations for whom use is contraindicated:

  • Patients with Glaucoma or obstructive uropathy.
  • Patients with obstructive diseases of the gastrointestinal tract, paralytic ileus, severe ulcerative colitis, toxic megacolon, or intestinal atony (of elderly or debilitated patients).
  • Patients with Myasthenia Gravis, myocardial ischemia, or unstable cardiovascular status in acute hemorrhage.

Age-related eligibility rules:

  • Use is often not recommended for children under 12 years of age.
  • Geriatric patients require cautious dose selection due to the greater frequency of decreased organ function.

Pregnancy and lactation eligibility status (if explicitly documented):

  • Pregnancy: Classified as Pregnancy Category C. Administration is advised only if clearly needed.
  • Lactation: The drug is excreted in human milk. Caution should be exercised when administered to a nursing woman.

Eligibility-related restrictions:

  • Use with caution is required for patients with impaired renal function (due to increased risk of toxic reactions), Coronary Heart Disease, Hypertension, Hyperthyroidism, and Autonomic Neuropathy.

Connection to the Overall Eligibility Profile

Official regulatory documents define non-eligibility through a mandatory list of contraindications targeting severe pre-existing diseases. For those not strictly prohibited, eligibility is conditional, requiring caution based on age, organ function, and specific comorbid conditions as detailed in the official prescribing information.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official interaction profile for Symax-SL (Hyoscyamine Sulfate) is structured primarily around additive pharmacodynamic effects and altered gastrointestinal absorption, as documented in regulatory labeling.

Drug-Drug and Pharmacodynamic Interactions

Co-administration with other medicines that possess anticholinergic properties may lead to additive adverse effects. This clinically significant pharmacodynamic interaction is documented for multiple categories, including certain Tricyclic Antidepressants, Monoamine Oxidase (MAO) Inhibitors, some Antihistamines, Phenothiazines, Haloperidol, and Amantadine.

Absorption-Based and Timing Interactions

Symax-SL’s action to decrease gastrointestinal motility may decrease the absorption of other orally administered medications. Conversely, the co-administration of Antacids (aluminum, magnesium, or calcium-containing preparations) may interfere with the absorption of Symax-SL, potentially leading to reduced exposure. To manage this, a mandatory timing separation rule is required: Symax-SL must be administered before meals, and Antacids must be administered after meals.

Interactions with Specific Substances

The regulatory profile also documents that the consumption of alcohol may increase central nervous system side effects such as drowsiness. Furthermore, co-administration with solid dosage forms of Potassium Chloride carries a documented risk of intensifying the local irritant effect, which can lead to gastrointestinal lesions.

Population-Specific Notes

In patients with impaired renal function, a condition often observed in the elderly, the risk of toxic reactions may be greater due to reduced drug clearance, requiring careful selection of treatment.

Mechanism of Action

How Symax-SL Works

Primary Molecular Interaction: The PTH1R Allosteric Site

Symax-SL is a small-molecule inhibitor that selectively modulates the parathyroid hormone type 1 receptor (PTH1R). It specifically binds to the allosteric site of PTH1R expressed on osteoclast precursor cells, leading to a direct and observable decrease in cAMP-mediated intracellular signaling.


Downstream Cellular Cascade

This molecular action modifies the signaling pathway responsible for osteoclast differentiation and function. The inhibition consequently initiates the apoptosis of mature osteoclasts. At a system level, this cascade influences the net balance between bone resorption and formation processes within the skeletal structure.

Dosage and Administration Information

How to Use Symax-SL: Administration Guidelines

Symax-SL (Hyoscyamine Sulfate) is administered primarily via the sublingual route using the Orally Disintegrating Tablet form. For this method, the tablet is placed under the tongue and allowed to dissolve completely. The dosage for adults and adolescents (12 years and older) is typically 0.125 mg to 0.25 mg per dose.

This medication is generally used on an as-needed (PRN) basis for acute symptomatic situations. Dosing frequency typically follows administration every four hours, with a strict maximum daily intake. The total dose administered in any 24-hour period must not exceed 1.5 mg (12 tablets). The timing of administration is often specified to occur 30 minutes to one hour before meals and at bedtime.

For patients in the older adult population, closer observation may be required during the administration of the standard regimen due to potential increased sensitivity. Furthermore, specific low-end dosing rules apply to the pediatric population (2 to under 12 years), with a maximum daily limit of 0.75 mg. If a dose is missed, the standard practice is to continue with the next scheduled dose and to never double the dose.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Symax-SL

Evidence for Use in Functional Gastrointestinal Disorders

This section will summarize the structure of the clinical research, including the historical randomized controlled trials and clinical experience, that examined the medicine in the context of conditions such as Irritable Bowel Syndrome (IBS) and other disorders marked by muscle hypermotility.

Research exploring Symax-SL (Hyoscyamine Sulfate) and its use in conditions characterized by fluctuating or episodic manifestations like IBS has included both historical Randomized Controlled Trials (RCTs) and general clinical trials. These studies focused on outcomes related to physical discomfort, specifically by measuring changes in abdominal pain and cramping scores, as well as by applying methods that assess patient-reported experiences of symptom relief. The populations observed in this research were primarily adults and adolescents aged 12 and older.

Findings derived from these studies describe patterns observed related to the body's involuntary smooth muscle and glandular tissues. The available evidence contributes to understanding symptom patterns observed in the studied populations over short-term periods. Because the agent was studied for a role as an adjunctive component of treatment, research highlights changes measured during the study period, helping to contextualize how patients reported their experience when symptoms became more noticeable.

Evidence for Use in Acute Visceral Spasms

This part will detail the research methodology, including the acute clinical trials and regulatory reviews, that explored the medicine's application during the symptomatic management of painful episodes such as Renal or Biliary Colic.

Symax-SL was studied for its use in research exploring short-term symptom changes related to acute episodes, such as Renal and Biliary Colic. Research examined its application in clinical trials conducted during periods of increased symptom activity in adults. The studies monitored outcomes related to episodic or acute changes, focusing on measurements of acute visceral pain and the reported change in spasm over a very short duration.

Studies conducted during these acute episodes show patterns related to the medicine's influence on smooth muscle contraction. Research highlights that the agent was observed in settings where temporary physiological imbalance was present. Findings often describe its use within a combined treatment approach that included other pain relief medications.

What Is Still Uncertain About Symax-SL

This concluding section will synthesize the main limitations of the research landscape, clarifying areas such as the need for larger-scale modern trials, the absence of specific long-term safety studies, and other key evidence gaps noted by regulatory authorities.

While studies contribute to the broader evidence landscape for Symax-SL, several aspects remain uncertain. Evidence quality varies across studies, with many of the core findings derived from older research methodologies that often featured sample sizes were modest. Comparative evidence is lacking for many of its uses, particularly against other existing pharmaceutical agents.

Additionally, a significant research limitation involves the absence of specific long-term studies. Regulatory reviews describe the explicit absence of long-term animal studies designed to examine the potential for carcinogenicity or mutagenesis. This means the long-term effects are not fully established, and there is limited information to characterize outcomes beyond short-term symptomatic use.

Key Studies & References Hyoscyamine Sulfate Sublingual Tablets: Official Medication Label (DailyMed, National Library of Medicine)

Frequently Asked Questions (FAQ)

Common questions about Symax-SL (FAQ)

Q: Is Symax-SL the same type of medicine as [similar drug name]?

A: Symax-SL is officially classified as an Anticholinergic and Antispasmodic medication. The active component is Hyoscyamine Sulfate, which is derived from a type of plant alkaloid. While other medicines may belong to the same general pharmacological group, each product has its own specific active ingredient and unique formulation.

Q: How long does it typically take before Symax-SL starts working?

A: Symax-SL is specifically designed as a sublingual tablet that dissolves quickly when placed under the tongue. This specialized administration route is intended to allow for a rapid onset of action. The official product information notes that the sublingual route is intended to allow for a rapid onset of action.

Q: Can Symax-SL be taken with food, or does it have to be on an empty stomach?

A: Official administration instructions often advise taking Symax-SL 30 minutes to one hour before meals and at bedtime. This timing is specified because it is important for the drug’s proper absorption. This timing is specified to align with conditions related to the drug’s intended absorption.

Q: What happens if I stop taking Symax-SL suddenly?

A: Symax-SL is primarily used on an as-needed (PRN) basis for acute symptoms. Regulatory instructions address missed doses, advising patients to simply continue with the next scheduled dose and to not double it. Information on potential withdrawal symptoms or rebound effects following the discontinuation of chronic use is not typically addressed in the regulatory summaries.

Q: What are the long-term safety expectations for Symax-SL?

A: Official regulatory reviews describe the absence of specific long-term animal studies designed to examine the potential for cancer or genetic changes. The long-term effects of the medication are not fully established in official regulatory documents, which is consistent with its use for short-term symptomatic relief.

Q: Does Symax-SL interact with common over-the-counter pain relievers like ibuprofen?

A: The official interaction profile notes that Symax-SL works by decreasing movement in the digestive system, which may decrease the absorption of other orally administered medications. Common over-the-counter pain relievers like ibuprofen are not explicitly listed in the drug interaction section of the product labeling.

Q: Do I need a special monitoring or testing while on Symax-SL?

A: The official product information mentions that certain groups, such as older adults or those with reduced kidney function, may require closer observation or careful dose selection. However, no specific routine laboratory tests, such as blood or urine tests, are listed as a mandatory requirement for the general patient population.

Q: Can Symax-SL affect blood pressure or blood sugar levels?

A: Official documentation advises caution for patients who have existing high blood pressure (hypertension) or heart conditions. Tachycardia, which is a fast heart rate, is listed as a documented adverse reaction. There is no information in the safety profile regarding effects on blood sugar levels.

Q: If I miss a dose of Symax-SL, what should I do?

A: The regulatory instructions clearly advise that if a dose is missed, patients should simply continue with their next scheduled dose. The instructions state that the dose is not to be doubled to compensate for a missed one.

Q: Is it common to feel tired when starting Symax-SL?

A: The official safety profile lists both drowsiness and weakness as documented adverse reactions affecting the nervous system. These effects are generally linked to the way the drug works, but the frequency with which patients experience them when starting the drug is not specified in regulatory summaries.

Q: Can Symax-SL affect my sleep?

A: The official safety information notes that drowsiness is a documented adverse reaction associated with Symax-SL. Any potential effects on sleep are typically related to the central nervous system effects that are documented in the product labeling.

Q: Are there any specific supplements or vitamins I should avoid while on Symax-SL?

A: The official drug interaction profile lists specific categories of medicines and substances, such as Antacids, that may interact with Symax-SL. General nutritional supplements or vitamins are not explicitly included in the regulatory warnings for drug interactions.

Q: Is Symax-SL known to interact with birth control pills?

A: The official interaction profile states that Symax-SL's action to decrease gastrointestinal movement may reduce the absorption of other oral medications. Hormonal contraceptives, such as birth control pills, are not explicitly named in the regulatory interaction profile.

Q: Is Symax-SL safe for people who have kidney issues?

A: Official documents require that caution be used for patients with impaired kidney function. This caution is related to the drug's clearance, as reduced kidney function may lead to a greater potential risk of toxic reactions.

Q: How long does the effect of one Symax-SL dose last?

A: The regulatory standard for administration frequency allows for a dose to be taken every four hours. This constraint on dosing frequency aligns with the expected duration of the drug's activity.

Q: Is there a generic version of Symax-SL available?

A: Symax-SL is the specific brand name for this sublingual formulation. The active ingredient, Hyoscyamine Sulfate, is a well-known compound that is widely available in generic form, though the specific formulation of Symax-SL is product-specific.

Q: What is the typical time frame a patient stays on Symax-SL?

A: Symax-SL is indicated for conditions that have fluctuating or episodic symptoms, and it is used on an as-needed basis for acute relief. Clinical studies have examined the medication over short-term periods, which is consistent with its role as a symptomatic relief agent.

Q: Does Symax-SL have a Black Box Warning?

A: The official labeling identifies serious adverse reactions, including psychosis and heat prostration. The specific regulatory designation of a Black Box Warning, the FDA's strongest safety warning, is not explicitly summarized in the core regulatory text.

Q: Are there any known severe drug interactions with Symax-SL that I should be aware of?

A: The regulatory profile documents that combining Symax-SL with solid dosage forms of Potassium Chloride carries a documented risk of potentially causing gastrointestinal lesions. Additionally, co-administration with other anticholinergic agents may lead to additive adverse effects.

Q: What are the signs of an allergic reaction to Symax-SL?

A: The official product information states that Symax-SL is contraindicated (must not be used) in patients who have a known hypersensitivity, which means a known allergy, to Hyoscyamine. Specific symptoms that define an allergic reaction are not typically detailed in the list of adverse reactions.

Q: Is Symax-SL considered a new drug or has it been on the market for a while?

A: The research evidence for Symax-SL includes findings that are based on historical randomized controlled trials and older research methodologies. This indicates that the active ingredient has been an established part of the medical landscape for a long period.

Q: Is Symax-SL safe to use with herbal remedies like St. John's Wort?

A: The official interaction profile is strictly limited to documented drug and substance interactions. Herbal products, such as St. John's Wort, are not explicitly listed or addressed in the regulatory interaction warnings.

Q: Can Symax-SL cause weight gain or loss?

A: The official safety profile provides a list of documented adverse reactions across several body systems, including gastrointestinal, nervous system, and cardiac effects. Weight gain or loss are not listed as documented adverse reactions in the official regulatory summaries.

How should Symax-SL be stored and disposed of?

Storage and Disposal Instructions for Symax-SL

The storage and disposal of Symax-SL (Hyoscyamine Sulfate Sublingual Tablets) must strictly adhere to regulatory requirements defined in the official labeling.


Required Storage Conditions

Condition Requirement (Official Labeling)
Temperature Store at Controlled Room Temperature between 20 C to 25 C (68 F to 77 F).
Container Must be kept in a tight, light-resistant container with a child-resistant closure.
Environment Must be stored away from excess heat and moisture.

Handling and Disposal

The medication must always be kept out of the reach of children, as required by the mandatory warning. In the event of an accidental overdose, the official instruction is to seek professional assistance or contact a Poison Control Center immediately. Unused or expired medication must be discarded properly, often through an approved drug take-back program.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Symax-SL found in:

A-Z Index: